About this Event
On Tuesday, August 25th,2026, FDA is conducting a hybrid public meeting on Patient-Focused Drug Development for Nonhealing Chronic Wounds. The purpose of this meeting is to provide FDA and other key stakeholders, including medical product developers, health care providers, and federal partners, the opportunity to hear directly from patients, patient representatives, and care partners about their experiences with nonhealing chronic wounds, including how the wounds and associated wound care affect their daily life, what matters most to them, their current approaches for managing or treating their nonhealing chronic wounds, and what they consider when determining whether to participate in a clinical trial.
There will be three sessions focused on:
(1) Health Effects and Daily Impacts
(2) Current Approaches to Treatment
(3) Perspectives on Clinical Trials
For each topic, a brief initial patient panel discussion will begin the dialogue. This will be followed by a facilitated discussion inviting comments from other patient and care partner participants in the audience. Panelists are also welcome to participate in the facilitated discussion.
If you are a patient or care partner interested in providing comments as part of the panel discussion, please indicate so during registration. A member of the PFDD Staff will contact you via email. Panelists will be confirmed prior to the meeting and will be invited to a brief, one-on-one call with our team to help them prepare for their role in the discussion.
For more information, please visit the FDA meeting website:
www.fda.gov/pfddchronicwounds
Event Venue & Nearby Stays
FDA White Oak Campus, 10903 New Hampshire Ave., Silver Spring, United States
USD 0.00
